NO20006452L - Inhibitorer av transkripsjonsfaktor NF-kB - Google Patents

Inhibitorer av transkripsjonsfaktor NF-kB

Info

Publication number
NO20006452L
NO20006452L NO20006452A NO20006452A NO20006452L NO 20006452 L NO20006452 L NO 20006452L NO 20006452 A NO20006452 A NO 20006452A NO 20006452 A NO20006452 A NO 20006452A NO 20006452 L NO20006452 L NO 20006452L
Authority
NO
Norway
Prior art keywords
disease
inhibitors
dermatosis
transcription factor
methods
Prior art date
Application number
NO20006452A
Other languages
English (en)
Other versions
NO20006452D0 (no
Inventor
James Francis Callahan
Marie C Chabot-Fletcher
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20006452D0 publication Critical patent/NO20006452D0/no
Publication of NO20006452L publication Critical patent/NO20006452L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)

Abstract

Det beskrives amino-indanon-inhibitorer av transkripsjonsfaktor NF-KB og farmasøytisk akseptable salter, hydrater og solvater derav, farmasøytiske prepara- ter av slike forbindelser, samt fremgangsmåter for behandling av sykdommer hvor aktivering av NF-tcB er implisert. Mer spesifikt beskrives fremgangsmåter for be- handling av en rekke sykdommer som er assosiert med NF-icB-aktivering, inklusi- ve inflammatoriske lidelser; spesielt reumatoid artritt; inflammatorisk tarmsykdom og astma; dermatose, inklusive psoriasis og akutt dermatose; autoimmune syk- dommer, vevs- og organavstøtning; Alzheimers sykdom; slag, aterosklerose; restenose; kreft, inklusive Hodgkins sykdom; og visse virusinfeksjoner, inklusive AIDS; osteoartritt; osteoporose; og Ataxia Telangiestasia, ved å administrere til en pasient som trenger det, en forbindelse i henhold til oppfinnelsen.
NO20006452A 1998-06-19 2000-12-18 Inhibitorer av transkripsjonsfaktor NF-kB NO20006452L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9001698P 1998-06-19 1998-06-19
PCT/US1999/013897 WO1999065495A1 (en) 1998-06-19 1999-06-18 INHIBITORS OF TRANSCRIPTION FACTOR NF-λB

Publications (2)

Publication Number Publication Date
NO20006452D0 NO20006452D0 (no) 2000-12-18
NO20006452L true NO20006452L (no) 2001-02-16

Family

ID=22220761

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006452A NO20006452L (no) 1998-06-19 2000-12-18 Inhibitorer av transkripsjonsfaktor NF-kB

Country Status (17)

Country Link
EP (1) EP1085872A4 (no)
JP (1) JP2002518333A (no)
KR (1) KR20010052990A (no)
CN (1) CN1306428A (no)
AR (1) AR019871A1 (no)
AU (1) AU4699699A (no)
BR (1) BR9911151A (no)
CA (1) CA2335293A1 (no)
CO (1) CO5080752A1 (no)
CZ (1) CZ20004760A3 (no)
HU (1) HUP0102492A2 (no)
IL (1) IL140324A0 (no)
NO (1) NO20006452L (no)
PL (1) PL345577A1 (no)
TR (1) TR200003779T2 (no)
WO (1) WO1999065495A1 (no)
ZA (1) ZA200007448B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU713471C (en) 1996-12-23 2002-04-18 Immunex Corporation Ligand for receptor activator of NF-kappa B, ligand is member of TNF superfamily
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
DK2009025T3 (da) 1998-05-14 2011-11-14 Immunex Corp Fremgangsmåde til hæmning af osteoklast-aktivitet
PT1782800E (pt) * 2000-01-24 2014-03-25 Genzyme Corp Métodos para detectar inibidores de jak3
US20060148732A1 (en) * 2000-11-17 2006-07-06 Gutterman Jordan U Inhibition of NF-kappaB by triterpene compositions
NZ530765A (en) 2001-06-26 2006-11-30 Amgen Fremont Inc Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
US7425580B2 (en) 2004-05-19 2008-09-16 Wyeth (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
WO2007097981A2 (en) 2006-02-16 2007-08-30 Millennium Pharmaceuticals, Inc. Alpha carbolines and uses thereof
BRPI0919282A2 (pt) 2008-10-02 2017-03-28 Asahi Kasei Pharma Corp composto, composição farmacêutica, inibidor de ikkb, método para inibir ikkb, métodos para prevenir e/ou tratar uma doença ou sintoma associado com nf-kb, uma doença ou sintoma associado com ikkb, e uma doença ou sintoma associado com reação inflamatória aguda ou crônica em mamíferos
WO2010108058A2 (en) * 2009-03-20 2010-09-23 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Small molecule inhibitors of dusp6 and uses therefor
US9186365B2 (en) * 2009-07-31 2015-11-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antiangiogenic small molecules and methods of use
WO2012109527A2 (en) 2011-02-10 2012-08-16 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Class of hdac inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
WO2014071000A1 (en) 2012-10-31 2014-05-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Class of hdac inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury

Also Published As

Publication number Publication date
EP1085872A4 (en) 2003-04-16
HUP0102492A2 (hu) 2001-11-28
NO20006452D0 (no) 2000-12-18
CZ20004760A3 (cs) 2001-08-15
PL345577A1 (en) 2001-12-17
IL140324A0 (en) 2002-02-10
BR9911151A (pt) 2001-03-06
CO5080752A1 (es) 2001-09-25
ZA200007448B (en) 2001-12-12
TR200003779T2 (tr) 2001-06-21
AR019871A1 (es) 2002-03-20
WO1999065495A1 (en) 1999-12-23
AU4699699A (en) 2000-01-05
CN1306428A (zh) 2001-08-01
EP1085872A1 (en) 2001-03-28
JP2002518333A (ja) 2002-06-25
CA2335293A1 (en) 1999-12-23
KR20010052990A (ko) 2001-06-25

Similar Documents

Publication Publication Date Title
NO20006451L (no) Inhibitorer av transkripsjonsfaktor NF-kB
NO20006452L (no) Inhibitorer av transkripsjonsfaktor NF-kB
MY138352A (en) Benzothiazole derivatives
NO20024808D0 (no) Fremgangsmåte ved syntesen av perindopril og farmasöytisk akseptable salter derav
NO20045434L (no) En kombinasjon av en NMDA-antagonist og acetylkolinesteraseinhibitorer for behandlingen av Alzheimers sykdom
GB0121033D0 (en) Organic compounds
MXPA04003439A (es) Compuestos de maleimida 3,4 disustituidos como antagonistas de receptor de quimiocina cxc.
WO2004045579A3 (en) Pharmaceutical compositions and dosage forms of thalidomide
GB0220187D0 (en) Organic compounds
MXPA05010958A (es) Derivados indazol como inhibidores jnk.
DE60214198D1 (de) Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen
TW200736196A (en) 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
MX2025000847A (es) Derivados de 3-(6-piridin-3-il)-2-[4-(4-metil-4h-1,2,4-triazol-3-il)piperidin-1-il]benzonitrilo y compuestos similares como inhibidores de qpctl y qpct para el tratamiento del cancer.
MXPA04002167A (es) Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
BR0109161A (pt) Beta-carbolinas substituìdas com atividade de inibição de ikb-quinase
PT1049703E (pt) Aldeido do acido n-¬2-(5-benziloxicarbonilamino-6-oxo-2-(4-fluorofenil)-1,6-di-hidro-1-pirimidinil)acetoxil|-l-aspartico como inibidor da enzima de conversao da interleucina-1beta in vivo
RU94045149A (ru) Средство ингибирования легочных гипертонических заболеваний
NO20055565L (no) Anvendelse av derivater av 2,4-dihydro-[1,2,4]triazol-3-thion som inhibitorer av enzymet myeloperoksidase (MPO)
JO2216B1 (en) 5 chloro-3 (4-methane sulfonyl phenyl) -6-methyl- (2.3)
AU2002218311A1 (en) Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease
MXPA04006555A (es) Piridazinodionas-3,4-disustituidas como antagonistas de receptor de quimiocina cxc.
Michaelides et al. Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors
ATE357453T1 (de) Comt-inhibitoren
MY133512A (en) Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors
PT1268472E (pt) Inibidores 3-aminopirazolicos de cinases dependentes da ciclina

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application